Here you will find current press releases and press kits of tesa Labtec GmbH.
EsoCap AG and tesa Labtec GmbH sign development cooperation agreement for a smart application technology in the upper gastrointestinal tract
EsoCap AG and tesa Labtec GmbH announced that they have entered into a cooperation on the industrial development of a unique drug delivery technology for diseases of the upper astrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film technology with an innovative biopharmaceutical company.
The German patch and thin-film maker announces the availability of a ropivacaine transdermal patch formulation for the treatment of neuropathic pain.
The German patch and oral thin film maker announces the completion of a Pre-Approval Inspection (PAI) by the US Food and Drug Administration (FDA) in February 2016.
The German patch and oral-film maker announces the opening of its own business development office in the US, targeting the biggest pharmaceutical market globally while improving customer focus.
tesa Labtec Opens LabFactory
Labtec GmbH has become a fully authorized manufacturer for transdermal drug delivery systems and oral dispersible films with its proprietary RapidFilm® technology.
Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch.
GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec.
APR Applied Pharma Research s.a. and Labtec GmbH announce the European Approval of Ondansetron Rapidfilm®, co-developed in partnership with MonoSol Rx and licensed to BioAlliance Pharma SA for EU countries.
Active ingredients pass through the skin or dissolve on the tongue
APR Applied Pharma Research s.a. and Labtec GmbH announce the successful completion of the pilot bioequivalence study of their Donepezil Rapidfilm® further confirming the validity and adaptability of this innovative proprietary technology.